X4A MARKETWIRE
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Co…
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation | $IBRX
CHART
$IBRX
Range
1 month
Chart loads when visible
Market data displayed by TradingView. Market data may be delayed.
SOURCE
Original Source
RELATED